Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

A Multi-center, Single-blind, Parallel-design, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate Oral Recombinant Microbial Lipase Efficacy in Patients With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00630279

Enrollment

Registered

2008-03-06

Start date

2008-02-29

Completion date

2009-03-31

Last updated

2009-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

Keywords

pancreatic exocrine insufficiency, chronic pancreatitis

Brief summary

This study is to estimate the efficacy of a number of doses in patients with pancreatic insufficiency

Interventions

DRUGPlacebo

Placebo

DRUGRecombinant Microbial Lipase SLV339

oral, 150 mg/d, 7 days treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subject \> 18 years; * Pancreatic exocrine insufficiency confirmed and documented in medical history by either a pathophysiological direct or indirect pancreatic function test or clinical symptoms of steatorrhea stool fat that resolved or improved substantially upon pancreatic enzyme supplementation; * Patients on a stable daily dose of pancreatic enzymes for 3 months; * Subjects with CP with or without partial pancreatectomy due to CP, confirmed in medical history by either CT , ERCP, plain film with pancreatic calcifications, ultra-sonography (calcifications, duct dilatation), magnetic resonance pancreatography, endoscope ultrasound, other radiological diagnosis captured by tools such as Cambridge classification and /or histology; * CFA \< 80% at time of randomization

Exclusion criteria

* Evidence of major surgery (except gall bladder removal or appendectomy) or other relevant diseases as revealed by history, physical examination, and laboratory assessments which may interfere with the absorption, distribution, metabolism or elimination of the study drug or constitute a risk factor when taking the study medication; * Investigational drug intake within 90 days prior to the pre-assessment visit; * Ileus or acute abdomen; * Allergic disease such as hypersensitivity pneumonitis, aspergillus mediated asthma or allergic broncho-pulmonary aspergillosis; * Stenosis or regurgitation of the esophagus or stomach; * Known HIV infection, acute phase of CP

Design outcomes

Primary

Measure	Time frame
CFA (Coefficient of Fat Absorption)	from baseline to end of 7 days treatment

Secondary

Measure	Time frame
CNA, stool fat, stool weight, nutritional parameters, clinical symptomatology	from baseline to end of 7 days treatment

Countries

Czechia, Denmark, Hungary, Latvia, Poland, Russia, Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026